Gilead and Galapagos’ Report Results of Filgotinib in P-III FINCH 3 Trial for Moderate-To-Severe Active Rheumatoid Arthritis (RA)

 Gilead and Galapagos’ Report Results of Filgotinib in P-III FINCH 3 Trial for Moderate-To-Severe Active Rheumatoid Arthritis (RA)

Gilead and Galapagos’ Report Results of Filgotinib in P-III FINCH 3 Trial for Moderate-To-Severe Active Rheumatoid Arthritis (RA)

Shots:

  • The P-III FINCH-3 study involves assessing of filgotinib (100/200 mg) + methotrexate (MTX) vs filgotinib (200mg)/MTX as monothx in 1252 patients in ratio (2:1:1:2) with moderate to severe active RA who are naive to MTX for @24 wks.
  • P-III FINCH 3 results: ACR20 (80.2%, 81.2% vs 78.1%/71.4%); ACR50 (57%,61.5% vs 58.1%/ 45.7%); ACR70 (40.1%, 43.8% vs 40%/26%); DAS28(CRP) < 2.6 (42.5%, 54.1% vs 42.4%/29.1%); HAQ-DI change (-0.90, -0.94 vs -0.89/ -0.79); mTSS change (0.22, 0.20 vs -0.04/0.52); SAEs (2.4%, 4.1% vs 4.8%/2.9%)
  • Filgotinib is an oral JAK1 inhibitor, evaluated in P-II EQUATOR study for psoriatic arthritis, P-III DIVERSITY study for Crohn’s disease. In Dec,2015 Gilead and Galapagos entered into a collaboration to develop and commercialize filgotinib

 Click here to read full press release/ article | Ref: Gilead | Image: Fortune

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post